Xeris Biopharma (XERS) said Monday that the US Food and Drug Administration has approved the company's supplemental new drug application for Gvoke VialDx for use as a diagnostic aid to temporarily inhibit gastrointestinal tract movement during radiologic examinations in adult patients.
Xeris also said it has partnered with American Regent to commercialize Gvoke VialDx in the US.
Xeris said it would handle product supply while American Regent would oversee commercialization.
Financial terms of the agreement were not disclosed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.